| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Anthony J Leonardi | Q110998653 | ||
| Pawel Muranski | Q114521246 | ||
| Sid P Kerkar | Q114521253 | ||
| Robert L Eil | Q114521256 | ||
| Eric Tran | Q114521258 | ||
| Nicolas Acquavella | Q114521260 | ||
| Ena Wang | Q114521261 | ||
| Nicholas P. Restifo | Q51142479 | ||
| Rahul Roychoudhuri | Q55486904 | ||
| David Clever | Q55998998 | ||
| Christopher A. Klebanoff | Q55999011 | ||
| Ken-Ichi Hanada | Q71142559 | ||
| Luca Gattinoni | Q85315718 | ||
| Madhusudhanan Sukumar | Q92575828 | ||
| Francesco Marincola | Q107723823 | ||
| Alena Gros | Q38801343 | ||
| Douglas Palmer | Q42598676 | ||
| P2093 | author name string | Joseph G Crompton | |
| Zhiya Yu | |||
| Douglas T Fearon | |||
| Ryan D Michalek | |||
| Trevor Upham | |||
| Mark S Sundrud | |||
| P2860 | cites work | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells | Q24530100 |
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Quantitative microplate-based respirometry with correction for oxygen diffusion | Q43069481 | ||
| CD4+ and CD8+ T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B | Q79803355 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| mTOR regulates memory CD8 T-cell differentiation | Q24648624 | ||
| Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice | Q28215433 | ||
| Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition | Q28474624 | ||
| Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems | Q33485414 | ||
| Enhancing CD8 T-cell memory by modulating fatty acid metabolism | Q33577204 | ||
| Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma | Q33806306 | ||
| Transcriptional control of effector and memory CD8+ T cell differentiation | Q34064074 | ||
| Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. | Q34151699 | ||
| Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism | Q34641201 | ||
| CD8+ T-cell memory in tumor immunology and immunotherapy | Q34768139 | ||
| Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infection | Q35012041 | ||
| Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients | Q35015778 | ||
| Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice | Q35223241 | ||
| Signal integration by Akt regulates CD8 T cell effector and memory differentiation. | Q35903157 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity | Q36490747 | ||
| Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients | Q36551911 | ||
| From cancer immunosurveillance to cancer immunotherapy | Q36990588 | ||
| The expansion and maintenance of antigen-selected CD8(+) T cell clones | Q36991440 | ||
| Advances in measuring cellular bioenergetics using extracellular flux | Q37110791 | ||
| CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. | Q37143600 | ||
| Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. | Q37200886 | ||
| Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy | Q37561102 | ||
| The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism | Q37792556 | ||
| Metabolism, migration and memory in cytotoxic T cells | Q37828371 | ||
| Role of PI3K/Akt signaling in memory CD8 T cell differentiation | Q38078934 | ||
| mTORC1 regulates CD8+ T-cell glucose metabolism and function independently of PI3K and PKB. | Q38091510 | ||
| Bioenergetic profile experiment using C2C12 myoblast cells | Q39614847 | ||
| Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development | Q40760682 | ||
| Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure | Q41494079 | ||
| Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells | Q42205546 | ||
| Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma | Q42445229 | ||
| Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. | Q42515219 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 296-305 | |
| P577 | publication date | 2014-11-28 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics | |
| P478 | volume | 75 |
| Q39136403 | 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. |
| Q46243384 | A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells |
| Q57135104 | AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8 T cells for adoptive immunotherapy |
| Q38848219 | Adoptive Cellular Therapy (ACT) for Cancer Treatment |
| Q26800611 | Adoptive T-cell therapy for cancer: The era of engineered T cells |
| Q34043643 | Adoptive cell transfer as personalized immunotherapy for human cancer |
| Q41850732 | Akt signaling is critical for memory CD8+ T-cell development and tumor immune surveillance |
| Q58883571 | Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity |
| Q49546319 | Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy |
| Q37032991 | BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers |
| Q28828457 | BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models |
| Q89029472 | Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy |
| Q64067972 | Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells |
| Q60047537 | CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success |
| Q64891859 | CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. |
| Q89128650 | CARs and other T cell therapies for MM: The clinical experience |
| Q26801436 | CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression |
| Q40583105 | CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells |
| Q28075479 | Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94 |
| Q37066925 | Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? |
| Q45870279 | Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy |
| Q40411216 | Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. |
| Q28391962 | Dynamic Metabolism in Immune Response |
| Q90334543 | Emerging Cellular Therapies for Cancer |
| Q89701989 | Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity |
| Q38828829 | Engineered T cells: the promise and challenges of cancer immunotherapy. |
| Q45871848 | Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy |
| Q36889204 | Enhancing adoptive T cell immunotherapy with microRNA therapeutics |
| Q49594681 | Epigenetic control of CD8+ T cell differentiation. |
| Q37713393 | Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. |
| Q28075992 | Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic |
| Q47152771 | Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. |
| Q42967415 | Fine-tuning the CAR spacer improves T-cell potency |
| Q61798873 | HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics |
| Q90660684 | Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells |
| Q98181408 | IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors |
| Q92486992 | IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype |
| Q92768544 | Immunometabolism: A new target for improving cancer immunotherapy |
| Q28068378 | Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination |
| Q88697390 | In Vitro Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness In Vivo |
| Q47290509 | Informatics for cancer immunotherapy |
| Q45875529 | Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy |
| Q38526844 | Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy |
| Q56886922 | Lack of Sprouty 1 and 2 enhances survival of effector CD8 T cells and yields more protective memory cells |
| Q46319985 | Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. |
| Q34473737 | Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape |
| Q36430680 | Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy |
| Q90716648 | Memory T cells: strategies for optimizing tumor immunotherapy |
| Q50700830 | Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. |
| Q39418546 | Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy |
| Q98196854 | Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy |
| Q92023481 | Metabolic interventions in the immune response to cancer |
| Q39244812 | Metabolic reprograming of anti-tumor immunity |
| Q97424076 | Metabolism of immune cells in cancer |
| Q46056233 | Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology |
| Q38713129 | Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function |
| Q36944440 | Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells |
| Q64054780 | NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs |
| Q92637629 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy |
| Q38646138 | Novel Treatments in Development for Melanoma. |
| Q38633355 | Obesity-associated cancer: an immunological perspective |
| Q91964127 | Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy |
| Q35756547 | Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity |
| Q60931648 | PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8 T-cell activity |
| Q42369747 | PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells |
| Q91079913 | Paths to expansion: Differential requirements of IRF4 in CD8+ T-cell expansion driven by antigen and homeostatic cytokines |
| Q54976860 | Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. |
| Q37012650 | Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. |
| Q38665128 | Predictors of tumor-infiltrating lymphocyte efficacy in melanoma |
| Q54959664 | Pushing the Limits of Cancer Therapy: The Nutrient Game. |
| Q39273837 | Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries |
| Q38928127 | Regulatory circuits of T cell function in cancer |
| Q57287788 | Reinforce the antitumor activity of CD8 T cells via glutamine restriction |
| Q91893532 | S-15 in combination of Akt inhibitor promotes the expansion of CD45RA-CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells |
| Q28087236 | Smart CARs engineered for cancer immunotherapy |
| Q40945758 | Special Conference on Tumor Immunology and Immunotherapy: A New Chapter |
| Q37043492 | Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. |
| Q26767514 | Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression |
| Q38531361 | Synthetic biology in cell-based cancer immunotherapy |
| Q97539453 | T Cell Metabolism in Cancer Immunotherapy |
| Q49713237 | T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties |
| Q26799575 | T cell metabolism drives immunity |
| Q39070577 | T memory stem cells in health and disease. |
| Q28081611 | T-cell receptor gene therapy--ready to go viral? |
| Q38488557 | TRUCKs: the fourth generation of CARs |
| Q37308185 | Targeting Akt in cell transfer immunotherapy for cancer |
| Q29248893 | Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy |
| Q57456561 | Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Anti-Tumor T Cell Response |
| Q38324388 | Targeting T cell metabolism for therapy |
| Q91814537 | Targeting mTOR and Metabolism in Cancer: Lessons and Innovations |
| Q92297313 | Targeting metabolism to regulate immune responses in autoimmunity and cancer |
| Q91137768 | Targeting mitochondria in cancer: current concepts and immunotherapy approaches |
| Q37677403 | Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion |
| Q39518049 | The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction |
| Q94524554 | The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy |
| Q41592770 | Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy |
| Q38901419 | Tissue-resident and memory properties of human T-cell and NK-cell subsets |
| Q26785545 | Trial Watch: Adoptive cell transfer for oncological indications |
| Q28077647 | Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity |
| Q96167005 | Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints |
| Q52314225 | Unraveling the Complex Interplay Between T Cell Metabolism and Function. |
| Q35719914 | mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation |
| Q33578997 | β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. |
Search more.